Real-life effectiveness and safety of dupilumab in adolescents with atopic dermatitis: a 52-week single-center retrospective study

J Dermatolog Treat. 2023 Apr 6;34(1):2200867. doi: 10.1080/09546634.2023.2200867.

Authors

Luigi Gargiulo^{1

2}, Carlo Alberto Vignoli^{1

2}, Luciano Ibba^{1

2}, Andrea Cortese^{1

2}, Mario Valenti^{1

2}, Antonio Costanzo^{1

2}, Alessandra Narcisi²

Affiliations

¹ Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, MI, Italy.
² Dermatology Unit, IRCCS Humanitas Research Hospital, Rozzano, MI, Italy.

PMID: 37026618
DOI: 10.1080/09546634.2023.2200867

No abstract available

Publication types

Letter

MeSH terms

Adolescent
Antibodies, Monoclonal / adverse effects
Antibodies, Monoclonal, Humanized / adverse effects
Dermatitis, Atopic* / drug therapy
Humans
Retrospective Studies
Severity of Illness Index
Treatment Outcome

Substances

dupilumab
Antibodies, Monoclonal, Humanized
Antibodies, Monoclonal